Lyxumia As Fourth GLP-1 To Market? Not To Worry, Says Zealand CEO

The Danish biotech has partnerships with major players in several therapeutic areas, including a successful tie-up with Sanofi, and is looking to partner some of its other pipeline programs as well.

Lyxumia, Sanofi’s newly approved Type 2 diabetes drug could become a blockbuster, although it is the fourth drug in its class to come to market, insists David Solomon, CEO of Zealand Pharma AS, which discovered the drug and licensed it in 2003 to a company that Sanofi later acquired.

The competition isn’t a hurdle because the market for glucagon-like peptide 1 agonists, the class of drugs including Lyxumia (lixisenatide),...

More from Archive

More from Pink Sheet